Table 3.
Characterization of the two citation cohorts.
| TBI publications with the most lifetime citations: n (%) | TBI publications with the highest annual citation rates: n (%) | ||
|---|---|---|---|
| Severity | Mild | 15 (30.0) | 18 (36.0) |
| Mild-to-moderate | 1 (2.0) | 0 (0.0) | |
| Mild-to-severe | 9 (18.0) | 14 (28.0) | |
| Moderate | 0 (0.0) | 0 (0.0) | |
| Moderate-to-severe | 2 (4.0) | 3 (6.0) | |
| Severe | 19 (38.0) | 11 (22.0) | |
| Unspecified | 4 (8.0) | 4 (8.0) | |
| Sample | Animal | 12 (24.0) | 5 (10.0) |
| Human | 38 (76.0) | 45 (90.0) | |
| Pediatric | 3 (7.9) | 4 (8.9) | |
| Sport | 9 (23.7) | 9 (20.0) | |
| Veteran | 3 (7.9) | 4 (8.9) | |
| Design | Case-series | 3 (6.0) | 1 (2.0) |
| Commentary | 0 (0.0) | 1 (2.0) | |
| Consensus statement/guidelines | 4 (8.0) | 6 (12.0) | |
| Cross-sectional | 0 (0.0) | 2 (4.0) | |
| Prospective cohort; uncontrolled | 14 (28.0) | 8 (16.0) | |
| Prospective cohort; controlled | 6 (12.0) | 4 (8.0) | |
| Randomized control trial | 5 (10.0) | 7 (14.0) | |
| Retrospective cohort | 2 (4.0) | 2 (4.0) | |
| Review | 6 (12.0) | 14 (28.0) | |
| Unspecified | 10 (20.0) | 5 (10.0) | |
| Country of correspondence | Australia | 2 (4.0) | 4 (8.0) |
| Belgium | 0 (0.0) | 1 (2.0) | |
| Canada | 2 (4.0) | 5 (10.0) | |
| Germany | 0 (0.0) | 1 (2.0) | |
| Israel | 0 (0.0) | 1 (2.0) | |
| Japan | 1 (2.0) | 0 (0.0) | |
| New Zealand | 2 (4.0) | 1 (2.0) | |
| United Kingdom | 9 (18.0) | 2 (4.0) | |
| United States of America | 34 (68.0) | 33 (66.0) | |
| Multi-national | 0 (0.0) | 2 (4.0) | |
| Product of international collaboration | 8 (16.0) | 14 (28.0) | |
| Average number of authors | 6.5 ± 6.2 | 10.3 ± 10.6 | |